πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Arrowhead Pharmaceuticals Ireland Patents

Full USPTO pharma patent portfolio for Arrowhead Pharmaceuticals Ireland β€” grant dates, expiration, and drug cross-links.

Patents
126
Expiring ≀24m
0

Quick answer

Arrowhead Pharmaceuticals Ireland has 126 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months β€” use filters for patent-cliff planning.

Page 2 of 3

  1. US 10308941

    Compositions and methods for inhibiting gene expression of factor XII

    Expires Mon May 30 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10294474

    Targeting ligands

    Expires Mon May 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10287582

    Organic compositions to treat HSF1-related diseases

    Expires Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10273482

    dsRNA for treating viral infection

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10246709

    Targeting ligands for therapeutic compounds

    Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10240153

    Organic compositions to treat APOC3-related diseases

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10138483

    Transferrin/transferrin receptor-mediated siRNA delivery

    Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10130651

    RNAi Therapy for Hepatitis B Virus Infection

    Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10081811

    Organic compositions to treat Beta-ENaC-related diseases

    Expires Mon Sep 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10047361

    Disulfide-containing alkyne linking agents

    Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10023862

    Organic compositions to treat beta-catenin-related diseases

    Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10022456

    Reversibly masked polymers

    Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10005815

    Biologically cleavable tetrapeptide linking agents

    Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10006025

    Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin

    Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9976141

    Compositions and methods for inhibiting gene expression of Hif2alpha

    Expires Mon May 17 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9938531

    Compositions and methods for inhibiting expression of RRM2 genes

    Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9932584

    Interfering RNA delivery system and uses thereof

    Expires Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9914927

    RNAi inhibition of alpha-ENaC expression

    Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9868949

    Organic compositions to treat EPAS1-related diseases

    Expires Mon Jan 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9803201

    Disulfide-containing alkyne linking agents

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9803205

    Compositions and methods for inhibiting gene expression of factor XII

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9795684

    Interfering RNA delivery system and uses thereof

    Expires Mon Oct 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9796756

    Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA

    Expires Mon Oct 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9765340

    RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disorders

    Expires Mon Sep 14 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9752147

    RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions

    Expires Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9752152

    Organic compositions to treat beta-ENaC-related diseases

    Expires Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9745585

    RNAi-mediated inhibition of histamine receptor H1-related conditions

    Expires Mon Aug 24 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9562230

    Transferrin/transferrin receptor-mediated siRNA delivery

    Expires Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9550994

    RNAI-mediated inhibition of frizzled related protein-1 for treatment of glaucoma

    Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9540643

    Organic compositions to treat HSF1-related diseases

    Expires Mon Jan 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9526799

    Low density lipoprotein receptor-mediated siRNA delivery

    Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9526796

    Peptide-based in vivo siRNA delivery system

    Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9487556

    Polyconjugates for delivery of RNAi triggers to tumor cells in vivo

    Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9476052

    RNAi inhibition of alpha-ENaC expression

    Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9476047

    RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions

    Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9474804

    Poly(vinyl ester) polymers for in vivo nucleic acid delivery

    Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9453220

    RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders

    Expires Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9452221

    Poly(acrylate) polymers for in vivo nucleic acid delivery

    Expires Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9447419

    RNAi-mediated inhibition of tumor necrosis factor Ξ±-related conditions

    Expires Mon Sep 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9422556

    RNAi-related inhibition of TNF-alpha signaling pathway for treatment of ocular angiogenesis

    Expires Mon Aug 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9376683

    Organic compositions to treat beta-ENaC-related diseases

    Expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9371529

    RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions

    Expires Mon Jun 16 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9347062

    Interfering RNA delivery system and uses thereof

    Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9345775

    Compositions for targeted delivery of siRNA

    Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9289514

    Low density lipoprotein receptor-mediated siRNA delivery

    Expires Mon Mar 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9249179

    Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA

    Expires Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9233170

    Interfering RNA delivery system and uses thereof

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9206428

    RNAi-mediated inhibition of histamine receptor H1-related conditions

    Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Arrowhead Pharmaceuticals Ireland have?

126 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Arrowhead Pharmaceuticals Ireland patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.